Literature DB >> 11170179

T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls.

N Hellings1, M Barée, C Verhoeven, M B D'hooghe, R Medaer, C C Bernard, J Raus, P Stinissen.   

Abstract

Myelin proteins, including myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) are candidate autoantigens in MS. It is not clear whether MS patients show a predominant reactivity to one or several myelin antigens. We evaluated the IFN-gamma production induced by MBP and MOG and selected MBP-, MOG- and PLP-peptides in MS patients and healthy controls using the IFN-gamma ELISPOT assay. Most MS patients and healthy controls showed a heterogeneous anti-myelin T-cell reactivity. Interestingly in MS patients a positive correlation was found between the anti-MOG and anti-MBP T-cell responses. No myelin peptide was preferentially recognized among the peptides tested (MBP 84-102, 143-168, MOG 1-22, 34-56, 64-86, 74-96, PLP 41-58, 184-199, 190-209). In addition the frequency of IL2R+ MBP reactive T-cells was significantly increased in blood of MS patients as compared with healthy subjects, indicating that MBP reactive T-cells exist in an in vivo activated state in MS patients. Most of the anti-MBP T-cells were of the Th1-type because reactivity was observed in IFN-gamma but not in IL-4 ELISPOT-assays. Using Th1 (IL-12) and Th2 (IL-4) promoting conditions we observed that the cytokine secretion pattern of anti-MBP T-cells still is susceptible to alteration. Our data further indicate that precursor frequency analysis of myelin reactive T-cells by proliferation-based assays may underestimate the true frequency of myelin specific T-cells significantly. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170179     DOI: 10.1002/1097-4547(20010201)63:3<290::AID-JNR1023>3.0.CO;2-4

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  38 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

Review 2.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

3.  miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.

Authors:  Kristen M Smith; Mireia Guerau-de-Arellano; Stefan Costinean; Jessica L Williams; Arianna Bottoni; Gina Mavrikis Cox; Abhay R Satoskar; Carlo M Croce; Michael K Racke; Amy E Lovett-Racke; Caroline C Whitacre
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 4.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

Review 5.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

6.  Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Authors:  Christopher T Harp; Sara Ireland; Laurie S Davis; Gina Remington; Bonnie Cassidy; Petra D Cravens; Olaf Stuve; Amy E Lovett-Racke; Todd N Eagar; Benjamin M Greenberg; Michael K Racke; Lindsay G Cowell; Nitin J Karandikar; Elliot M Frohman; Nancy L Monson
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

7.  Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.

Authors:  M C González-Oria; M Márquez-Coello; J A Girón-Ortega; J Argente; M Moya; José-Antonio Girón-González
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-16       Impact factor: 4.147

Review 8.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

9.  Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis.

Authors:  Laure Michel; Laureline Berthelot; Ségolène Pettré; Sandrine Wiertlewski; Fabienne Lefrère; Cécile Braudeau; Sophie Brouard; Jean-Paul Soulillou; David-Axel Laplaud
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

10.  Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy.

Authors:  James R Tonra
Journal:  Cerebellum       Date:  2002 Jan-Mar       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.